SYST-iMYC SIGNED
Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SYST-iMYC project word cloud
Explore the words cloud of the SYST-iMYC project. It provides you a very rough idea of what is the project "SYST-iMYC" about.
Project "SYST-iMYC" data sheet
The following table provides information about the project.
| Coordinator |
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 148˙875 € |
| EC max contribution | 148˙875 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2018-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-07-01 to 2019-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON | ES (BARCELONA) | coordinator | 148˙875.00 |
Map
Project objective
Current cancer therapies target redundant cellular functions often compensated for by cancer cells, resulting in resistance to treatment. Here we propose an innovative approach to inhibit Myc, a non-redundant and “most-wanted” therapeutic target for human cancer. Targeting Myc has long been considered unfeasible because of the potentially catastrophic side effects in normal tissues. Against this dogma, we showed that Myc inhibition by Omomyc, a Myc mutant designed by Dr. Soucek, has a dramatic therapeutic impact in multiple mouse models of cancer, while causing only limited and reversible side effects. Critically, there is no emergence of resistance. Thanks to the ERC-2013-CoG n° 617473, we discovered the unexpected cell-penetrating properties of the purified Omomyc polypeptide. Moreover, we found that it is anti-tumorigenic after local (intranasal) delivery to mouse models of lung and brain tumors, and could therefore become the first clinically-viable direct Myc inhibitor. With this ERC PoC, we propose to develop a new drug based on an Omomyc variant that enables systemic treatment of several cancer types including lymphoma, breast, and melanoma. In all these cancers Myc contributes to multiple aspects of tumorigenesis including immune suppression. At the end of this project we will have a patent protected therapeutic polypeptide active in vitro and in vivo and ready to enter clinical trials Phase I/II in patients and to continue its commercialization. The forecasted peak revenue for such first-in-class drug in those indications reaches 2.612 M€ annually. With this ERC PoC project we will achieve essential milestones to develop this innovative therapeutic polypeptide by establishing the feasibility, including a commercial data package and cost estimations for the industrial production. Passing these milestones will de-risk the product and increase its value and probability of reaching the market by making it ready to be transferred to a spin-off company.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Mireia Pesarrodona, Toni Jauset, Zamira V. DÃazâ€Riascos, Alejandro Sánchezâ€Chardi, Marieâ€Eve Beaulieu, Joaquin Serasâ€Franzoso, Laura Sánchezâ€GarcÃa, Ricardo Baltà â€Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz, Laura Soucek, Antonio Villaverde, Ibane Abasolo, Esther Vázquez Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies published pages: 1900849, ISSN: 2198-3844, DOI: 10.1002/advs.201900849 |
Advanced Science 6/18 | 2020-03-05 |
| 2019 |
S. Ramón y Cajal, P. Sancho, L. Soucek, H. Peinado, M. Abad, M. Valiente, A. Efeyan, J. Pardo, V. Quesada, J. Jimeno, P. M. Duque, A. Antón, I. Varela, A. J. Schuhmacher A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas published pages: , ISSN: 1699-048X, DOI: 10.1007/s12094-019-02199-4 |
Clinical and Translational Oncology | 2020-02-28 |
| 2018 |
SÃlvia Casacuberta-Serra, Laura Soucek Myc and Ras, the Bonnie and Clyde of immune evasion published pages: S457-S459, ISSN: 2218-676X, DOI: 10.21037/tcr.2018.03.09 |
Translational Cancer Research 7/S4 | 2020-02-28 |
| 2019 |
Marie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, Sandra MartÃnez-MartÃn, Peter Rahl, Loïka Maltais, Mariano F. Zacarias-Fluck, SÃlvia Casacuberta-Serra, Erika Serrano del Pozo, Christopher Fiore, Laia Foradada, Virginia Castillo Cano, Meritxell Sánchez-Hervás, Matthew Guenther, Eduardo Romero Sanz, Marta Oteo, Cynthia Tremblay, Génesis MartÃn, Danny Letourneau, Martin Montagne, Migu Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy published pages: eaar5012, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aar5012 |
Science Translational Medicine 11/484 | 2020-02-28 |
| 2019 |
Jonathan Whitfield, Laura Soucek Editorial overview: Peptides in cancer published pages: iii-v, ISSN: 1471-4892, DOI: 10.1016/j.coph.2019.06.001 |
Current Opinion in Pharmacology 47 | 2020-02-28 |
| 2019 |
Marie-Eve Beaulieu, Laura Soucek Finding MYCure published pages: e1618178, ISSN: 2372-3556, DOI: 10.1080/23723556.2019.1618178 |
Molecular & Cellular Oncology 6/5 | 2020-02-28 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYST-IMYC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SYST-IMYC" are provided by the European Opendata Portal: CORDIS opendata.